RUSH

RUSH Institutional Biosafety Committee (IBC)	
Meeting Date	June 18, 2025
Meeting Time	12:00 PM – 1:00 PM
Meeting Type	Virtual via Microsoft Teams
IBC Members Present	1. Amarjit Virdi, Ph.D. (IBC Chair) 2. Ed R. Blazek, Ph.D., SM (NRCM) (BSO) 3. James Bremer, Ph.D. (IBC Member / Virology) 4. Christopher Forsyth, Ph.D. (IBC Member / Microbiology/Immunology) 5. João Mamede, Ph.D. (IBC Member / Recombinant DNA Technologies) 6. Jeffrey Oswald, D.V.M., Comparative Research Center (IBC Member / Veterinary Medicine) 7. Adam Roubitchek, Ed.D. (Local Non-Affiliated Member) 8. Jennifer Strong (*ex officio* non-voting / Research Compliance) 9. Brett Williams, M.D. (IBC Member / Infectious Disease Physician)
Quorum	Quorum was declared by the Chair. The IBC has nine voting members, and five members are required to conduct business.
Other Individuals in Attendance	1. Christine VanTubbergen, MPH (Program Manager, Office of Research Affairs) 2. Rebecca 'Bex' Ober, D.V.M. (Senior Director, Comparative Research Center)
Call to Order	The IBC Chair called the meeting to order at 12:01 PM.
Conflicts of Interest	The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.
Review and Approval of Previous Meeting Minutes	May 28, 2025 Motion: Approve the minutes as circulated. Votes: 8-0-0-0 (for-against-abstain-recuse)

Review of Prior Business		
PI Name & ORA #	**Application**	**Approval Date**
Sunita Nathan, M.D. 21070206-IBC18	Amendment 14	6/6/25
Patrick Moore, M.D. 24082607-IBC03	Amendment 03	6/6/25
Thomas Westbrook, M.D. 24032202-IBC02	Amendment 01	6/6/25
Elizabeth Berry-Kravis, M.D. Ph.D. 23092006-IBC14	Amendment 12	6/5/25
Elizabeth Berry-Kravis, M.D. Ph.D. 24022207-IBC04	Amendment 03	6/5/25
Peter Reisz, M.D. 23022101-IBC06	Amendment 05	6/2/25

New IBC Applications for Review	
PI Name	Gary Steinberg, M.D.
ORA#	New Initial Application 25041701-IBC01
Project Overview	**III-C-1** This is a multi-arm, open-label, Phase II clinical trial designed to assess the safety and efficacy of cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer (NMIBC). In January 2024, the FDA granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec. This trial is sponsored by CG Oncology, Inc. (ClinicalTrials.gov ID: NCT06567743). DDM (N-dodecyl-β-D-maltoside), a nonionic surfactant, will also be administered alongside cretostimogene grenadenorepvec. DDM is considered an excipient by the FDA. Cohort CX will assess concurrent or sequential treatment of cretostimogene grenadenorepvec and DDM with gemcitabine, a chemotherapy drug, for the first time. Drugs will be administered by intravesical treatment. Cretostimogene grenadenorepvec is a drug consisting of a recombinant, conditionally replicating oncolytic adenovirus. In cretostimogene grenadenorepvec, the viral E1A promoter has been replaced by the human E2F-l promoter which then drives expression of the essential El viral genes and restricts viral replication to retinoblastoma (Rb)/E2F pathway defective tumor cells, selectively killing these cells with minimal damage to normal tissues. In addition to restricted replication, cretostimogene grenadenorepvec also selectively expresses the human cytokine GM-CSF, which may induce a systemic anti-tumor immune response by activating immune cells. The local expression of GM-CSF by cretostimogene grenadenorepvec-infected cells is expected to induce local inflammatory responses, thereby enhancing the local anti-tumor activity of the vector. Additionally, GM-CSF secreted by cretostimogene grenadenorepvec-infected tumor cells can attract antigen presenting cells to the tumor site and lead to the priming of naïve effector T cells. Expression of the GM-CSF transgene is controlled by the endogenous viral E3 promoter. Since the E3 promoter is in turn activated by E1A, both viral replication and GM-CSF expression are ultimately under the control of the tumor-selective E2F-1 promoter. Tumor selectivity of cretostimogene grenadenorepvec is based on the use of the E2F-1 promoter to control viral replication. Cretostimogene grenadenorepvec will be prepared for intravesicle administration under BSL-2 conditions.
NIH Guidelines Section	**III-C-1**
Risk Assessment & Discussion	• Adenovirus is a RG-2 agent. • Agent will be prepared in a BSL-2 biosafety cabinet. • Syringe preparation will be performed in a BSL-2 biosafety cabinet. • PPE consisting of gloves, gown, surgical mask, and eye protection will be utilized when preparing or administering the agent. • Universal precautions and contact precautions will be observed when working directly with the agent or when handling participant urine for at least 1 week after administration. • All materials that come into contact with the agent, including used vials, syringes and infusion bags, will be disposed of as biohazardous waste.

	• Although there has been no documented person-to-person transmission of cretostimogene grenadenorepvec, patients will be educated on infection control precautions
Training	For research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and clinical lab personnel must complete the CITI Basic Biosafety Training course. One individual must renew their CITI International Air and Transportation Association (IATA) training.
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	• BL2 for preparation of the agent.

IBC Vote	• A motion was made to provisionally approve this application pending the following conditions be met:
	  • Submission of the informed consent form (ICF) on the Rush template
	  • Addition of potential interactions between agent and gemcitabine to the ICF, as this will be the first in human combination treatment of these drugs
	  • Specification of use of condoms, instead of generic 'barrier contraception,' in the ICF
	  • Renewal of IATA training for one individual
	  • Submission of current biosafety cabinet certification
	Votes:
	• 8-0-0-0
	Conflicts of Interest: None

New Business	• The new veterinarian and Senior Director of the Comparative Research Center, Dr. Rebecca 'Bex' Ober, was introduced to the Committee and attended the meeting as a guest.
Review of Incidents	Nothing to report.
Inspections/Ongoing Oversight	Nothing to report.
IBC Training	No trainings were conducted.
Public Comments	There were no public comments.
Adjournment	The IBC Chair moved to adjourn the meeting at 12:57 PM The next meeting scheduled is for July 30, 2025 at 12:00 PM via Microsoft Teams.